This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Immunization  • Medical Practice, Other  • Alert me on articles by topic

Ru-Chien Chi, MD, MS; Kathleen M. Neuzil, MD, MPH; Benjamin A. Lipsky, MD; Gayle E. Reiber, MPH, PhD

Arch Intern Med. 2007;167(21):2366-2368.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The United States has recently experienced influenza vaccine shortages because of manufacturing problems and distribution delays.¹ During the 2004-2005 season, only 61 of the expected 100 million influenza vaccine doses were available to the US market after 1 of the 2 licensed companies withdrew their product.^1-2 The Centers for Disease Control and Prevention (CDC) recommended that available vaccine be reserved for persons at high risk for influenza-related complications and close contacts of high-risk persons.¹ That year, vaccine coverage levels were lower among those prioritized for influenza vaccination, including older adults, long-term care residents, and health care workers.^3-4 Only 63% of elderly persons and 46% of adults with chronic conditions who tried were able to obtain the influenza vaccine. Half of adults in high-risk groups did not attempt to get the vaccine, often . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION